Risk of major adverse cardiovascular events with aripiprazole versus olanzapine, quetiapine, and risperidone in severe mental illness: a target trial emulation
Alvin Richards-Belle, Naomi Launders, Sarah Hardoon, Kenneth K C Man, Neil M Davies, Elvira Bramon, Joseph F Hayes, David P J Osborn · 2025
Read Risk of major adverse cardiovascular events with aripiprazole versus olanzapine, quetiapine, and risperidone in severe mental illness: a target trial emulation by Alvin Richards-Belle, Naomi Launders, Sarah Hardoon, Kenneth K C Man, Neil M Davies, Elvira Bramon, Joseph F Hayes, David P J Osborn (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12852762.txt.
Description
Alvin Richards-Belle and co-authors compare heart risk across antipsychotic drugs in a 2025 study. Records covered 20,404 patients with severe mental illness from 2005 to 2014. The design emulates a randomized trial using routine data.
Starting aripiprazole was compared with three other common drugs. The outcome was five-year risk of major cardiovascular events. Events combined heart attack and stroke admissions with cardiovascular death. Aripiprazole starters showed a similar risk to olanzapine starters. Other comparisons are reported in the same framework. Readers get long-term safety evidence to weigh alongside symptom control.
Catalog record
| CREATOR | Alvin Richards-Belle, Naomi Launders, Sarah Hardoon, Kenneth K C Man, Neil M Davies, Elvira Bramon, Joseph F Hayes, David P J Osborn |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |